GET DAILY SIGNALSLineage Cell Therapeutics (LCTX): +7.6% Move Over 30 Days as Pipeline Progresses
Key Takeaways
- Lineage Cell Therapeutics is a clinical-stage biotechnology company advancing "off-the-shelf" (allogeneic) cell therapies for serious neurological and ophthalmic conditions.
- Shares have moved roughly +7.6% over the trailing 30 days, rising from about $0.95 to $1.02, while remaining well below the top of their 52-week range of approximately $0.88 to $1.99.
- Lead candidate OpRegen is in Phase 2a development for geographic atrophy (dry age-related macular degeneration) under a worldwide collaboration with Roche and Genentech.
- The company is scheduled to report third-quarter 2026 financial results and a business update on November 12, 2026.
- Available analyst consensus data reflects a "Strong Buy" rating, with an average 12-month price target of approximately $5.50 across seven analysts.
- A diversified pipeline that includes OPC1, ReSonance (ANP1), COR1, and ILT1 extends the company's reach beyond ophthalmology.
- For additional detail, explore Lineage Cell Therapeutics' Price Targets, Earnings, and Forecast pages.
- Readers can also explore Trending AI Robots to see how algorithmic strategies are positioning across the market.
Current Market Snapshot
LCTX trades on the NYSE American under the symbol LCTX, with shares hovering near $1.02 and a market capitalization of roughly $258 million. The stock has been range-bound in recent months, oscillating between the low $0.90s and just above $1.00, and it currently sits closer to the lower end of its 52-week range. With a beta near 1.7, LCTX tends to be more volatile than the broader market, a common characteristic of clinical-stage biotechs whose valuations hinge on trial data, partnerships, and financing rather than near-term profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Lineage Cell Therapeutics (LCTX) Business Overview and Competitive Position
Headquartered in Carlsbad, California, Lineage Cell Therapeutics develops allogeneic cell replacement therapies built on its proprietary AlloSCOPE platform, which emphasizes scalable, consistent, "off-the-shelf" pluripotent cell engineering and in-house manufacturing. The company's most advanced asset is OpRegen, a retinal pigment epithelial (RPE) cell therapy being evaluated in a Phase 2a study for geographic atrophy secondary to dry age-related macular degeneration. The program is partnered with Roche and Genentech, providing external validation and milestone-driven economics. Beyond ophthalmology, the pipeline includes OPC1 (oligodendrocyte progenitor cells for spinal cord injury), ReSonance (ANP1, an auditory neuron progenitor therapy for hearing loss being developed with William Demant Invest A/S), COR1 (corneal endothelial disease), ILT1 (an islet cell initiative targeting Type 1 diabetes), and earlier-stage programs PNC1 and RND1. This breadth, combined with a strong cash position, positions Lineage among the more diversified pure-play cell therapy developers. From what I see, the platform's in-house capabilities stand out as a potential differentiator.
Recent Developments Driving LCTX
Several verified developments have shaped sentiment around LCTX in recent weeks. On November 5, 2026, the company announced it would report third-quarter 2026 results and host a business update call on November 12, 2026. Earlier in the period, Lineage provided an update on its ReSonance program for hearing loss, its first internally developed cell transplant built on the AlloSCOPE platform, and announced that the U.S. Patent and Trademark Office issued a patent covering its AlloSCOPE 5D manufacturing platform. In its second-quarter 2026 report, management highlighted continued progress on OpRegen under the Roche collaboration, rapid advancement of COR1 and ILT1, and a shift toward chronic spinal cord injury patients for OPC1, while noting a cash runway extending into the third quarter of 2028. I'm watching this closely for any updates on the upcoming call.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary catalysts for LCTX center on clinical execution and partnership milestones. The OpRegen program remains the central value driver, and investors will monitor updates from Roche and Genentech on the Phase 2a GAlette study, including enrollment progress and any data readouts. The ongoing DOSED study for OPC1, particularly its shift toward chronic spinal cord injury patients, represents another area of clinical focus, while preclinical data for COR1 is expected to provide further insight into the platform's manufacturing scalability. Near term, the November 12, 2026 earnings report and business update will be closely watched for cash position, revenue recognition, and guidance. Broader considerations include biotech sector sentiment, interest-rate dynamics affecting capital-intensive development-stage companies, and competitive activity in the geographic atrophy and cell therapy markets. As with all clinical-stage biotechs, trial setbacks, regulatory decisions, and financing needs remain key risks. One thing that stands out is how the Roche partnership could influence timelines.
Using Tickeron AI Tools for Biotech Analysis
In my own work tracking names like LCTX, I have found Tickeron's AI Trend Prediction Engine helpful for assessing potential momentum shifts based on historical patterns and current data. It provides an additional layer of systematic insight that complements traditional fundamental review, especially for volatile small-cap biotechs where trial updates can drive sharp moves. This approach has allowed me to cross-check price behavior against broader sector signals without relying solely on manual charting.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for LCTX turns positive, indicating new upward trend
LCTX saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 118 similar instances where the indicator turned positive. In 96 of the 118 cases, the stock moved higher in the following days. The odds of a move higher are at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LCTX just turned positive on October 08, 2026. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
LCTX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LCTX crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +4.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 158 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 125 of 156 cases where LCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 57 of 66 cases where LCTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.235) is normal, around the industry mean (3.482). P/E Ratio (-7.286) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions
Industry Biotechnology
Advertisement